Acerus Pharmaceuticals (TSX:ASP) ROCE % : -38.49% (As of Sep. 2022)

View and export this data going back to 2009. Start your Free Trial

What is Acerus Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Acerus Pharmaceuticals's annualized ROCE % for the quarter that ended in Sep. 2022 was -38.49%.

Acerus Pharmaceuticals ROCE % Historical Data

The historical data trend for Acerus Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acerus Pharmaceuticals ROCE % Chart

Acerus Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

ROCE %

Get a 7-Day Free Trial

-39.75

-125.01

-150.27

-253.68

-862.03

Acerus Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
ROCE %	Get a 7-Day Free Trial															-	-	-181.51	-106.91	-38.49

Acerus Pharmaceuticals ROCE % Calculation

Acerus Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	-41.188	/	( ( (21.752 - 9.098)	+	(12.355 - 15.453) )	/ 2 )
	=	-41.188	/	( (12.654	+	-3.098)	/ 2 )
	=	-41.188	/	4.778
	=	-862.03 %

Acerus Pharmaceuticals's ROCE % of for the quarter that ended in Sep. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2022 )		(Q: Jun. 2022 )		(Q: Sep. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2022 )		(Q: Jun. 2022 )		(Q: Sep. 2022 )
	=	-14.108	/	( ( (58.17 - 27.836)	+	(63.587 - 20.611) )	/ 2 )
	=	-14.108	/	( ( 30.334	+	42.976 )	/ 2 )
	=	-14.108	/	36.655
	=	-38.49 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2022) EBIT data.

Acerus Pharmaceuticals (TSX:ASP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Acerus Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Acerus Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Acerus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acerus Pharmaceuticals Corp (TSX:ASP) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

7025 Langer Drive, Suite 205, Mississauga, ON, CAN, L5N 0E8

Website

https://www.aceruspharma.com

Acerus Pharmaceuticals Corp is a specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of branded products that improve patient experience, with a primary focus on the field of men's health. Its foundational product includes NATESTO, a testosterone therapy based on nasal gel technology. The company commercializes its products via its salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.

Executives

Norma Beauchamp	Director
Stephen Robert Gregory	Director
Edward Joseph Gudaitis	Director, Senior Officer